# Study to Assess the Safety and Tolerability of MBF-015 in Healthy Young Volunteers

> **NCT06049147** · PHASE1 · COMPLETED · sponsor: **Medibiofarma S.L.** · enrollment: 72 (actual)

## Conditions studied

- Safety and Pharmacokinetic

## Interventions

- **DRUG:** MBF-015 4 mg oral capsule
- **DRUG:** MBF-015 16 mg oral capsule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06049147
- **Lead sponsor:** Medibiofarma S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-07
- **Primary completion:** 2023-08-24
- **Final completion:** 2023-08-24
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06049147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06049147, "Study to Assess the Safety and Tolerability of MBF-015 in Healthy Young Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06049147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*